FDA Clearance Tracker · P160053-S002
MagtraceTM and Sentimag(R) Magnetic Locatization System
Last checked: Nov 20, 2026Latest source record: Dec 6, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Dec 6, 2022
Approved
Time to decision
1,559 days
Received Aug 30, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P160053-S002
- Device name
- MagtraceTM and Sentimag(R) Magnetic Locatization System
- Applicant
- Endomagnetics Ltd.,
- Applicant location
- Cambridge
- Received
- Aug 30, 2018
- Decided
- Dec 6, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160053
Device type
- Device class
- Class III
- Specialty
- General & Plastic Surgery
FDA's approval statement
As written in FDA's record.
Approved to assist in localizing lymph nodes draining a tumor site, as part of a sentinel lymph node biopsy procedure, in patients with breast cancer undergoing a mastectomy or lumpectomy. For patients undergoing lumpectomy, nipple sparing, nipple areolar sparing or skin sparing procedures, Magtrace is indicated to be injected only peritumorally.
Source documents
Other decisions for Endomagnetics Ltd.,
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K232865 · Decided Jun 28, 2024 · 287 days after receipt
Device type: Marker, Radiographic, Implantable (NEU) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.